How has J.B. Chemicals & Pharmaceuticals Ltd. (JBCHEPHARM) been performing? We dig into revenue, profitability, valuation, and ownership trends.
JB Chemicals Revenue Trend
Revenue rose 11.3% to ₹3,918 Cr in FY2025 for J.B. Chemicals & Pharmaceuticals Ltd., against ₹3,521 Cr the year before.
Revenue compounded at 13.1% annually over 10 years for J.B. Chemicals & Pharmaceuticals Ltd.. That's a strong growth rate that comfortably outpaces inflation.
In terms of scale, J.B. Chemicals & Pharmaceuticals Ltd.'s ₹3,918 Cr in annual revenue positions it as a mid-sized pharmaceuticals company.
It's been 10 years of continuous revenue growth for J.B. Chemicals & Pharmaceuticals Ltd. — a pattern worth noting.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹3,918 Cr | +11.3% |
| FY2024 | ₹3,521 Cr | +11.5% |
| FY2023 | ₹3,159 Cr | +28.2% |
| FY2022 | ₹2,463 Cr | +20.6% |
| FY2021 | ₹2,043 Cr | — |
View J.B. Chemicals & Pharmaceuticals Ltd.'s full 10-year revenue trend with CAGR analysis →
JB Chemicals Profitability
J.B. Chemicals & Pharmaceuticals Ltd.'s bottom line improved to ₹660 Cr in FY2025, a 19.4% increase over the prior year.
Net profit margin improved to 16.8% in FY2025 from 15.7% in FY2024, indicating better cost control.
The diluted EPS figure moved up to ₹41.56 in FY2025, against ₹34.85 posted in FY2024.
Is JB Chemicals Undervalued
Based on the P/E Ratio model, J.B. Chemicals & Pharmaceuticals Ltd.'s fair value works out to ₹1,725 — 19.4% downside from where it trades today.
J.B. Chemicals & Pharmaceuticals Ltd. shares are currently trading at ₹2,140.00.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹1,725 | 19.4% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for J.B. Chemicals & Pharmaceuticals Ltd. with detailed assumptions →
JB Chemicals Shareholding Pattern
Promoters have been buying — their stake moved up from 47.7% to 48.8% over 4 quarters.
FII ownership stands at 16.3%, down from the 17.8% recorded a year ago.
On the domestic institutional side, the holding is 21.4% as of March 2026 — up from 19.6%.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 48.8% | 16.3% | 21.4% | 13.5% |
| Dec 2025 | 47.5% | 14.9% | 23.4% | 14.2% |
| Sep 2025 | 47.6% | 15.3% | 22.8% | 14.3% |
| Jun 2025 | 47.7% | 17.8% | 19.6% | 14.9% |
Track quarterly shareholding changes for J.B. Chemicals & Pharmaceuticals Ltd. →
JB Chemicals Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
In FY2025, the total asset base came in at ₹42.74B, up 7.0% YoY from ₹39.94B.
Intangibles & Goodwill accounts for 31.8% of the total, ahead of Receivables (19.1%) and Property, Plant & Equipment (14.9%).
Capital structure: 80.3% equity, 0.7% debt, 19.0% operating liabilities. Over the year, debt is down 92.6% and equity is up 17.4%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 4.32B |
| Receivables | 8.15B |
| Inventories | 5.29B |
| Property, Plant & Equipment | 6.38B |
| Investments | 279.80M |
| Intangibles & Goodwill | 13.58B |
| Other Assets | 4.73B |
| Category | Value |
|---|---|
| Equity | 34.33B |
| Short-term Debt | 215.37M |
| Long-term Debt | 63.53M |
| Trade Payables | 4.11B |
| Other Liabilities | 4.02B |
What Stands Out About JB Chemicals
In summary, J.B. Chemicals & Pharmaceuticals Ltd. (JBCHEPHARM) presents the following picture for fundamental analysts.
Revenue of ₹3,918 Cr in FY2025, up 11.3% year-over-year.
Long-term revenue has been compounding at 13.1% annually over 10 years.
The company is profitable, with a net margin of 16.8% and net income of ₹660 Cr.
The P/E Ratio model implies 19.4% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
There's more to the story. Craytheon's full profile for J.B. Chemicals & Pharmaceuticals Ltd. includes three valuation models, decade-long financials, and insider activity.